Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SHE:300534)
China · Delayed Price · Currency is CNY 9.65
+0.15 (1.58%)
Apr 10, 2026, 12:19 PM CST
SHE:300534 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 886.96 | 1,024 | 1,067 | 788.26 | 280.05 |
Other Revenue | - | 15.21 | 12.89 | 11.42 | 7.77 |
| 886.96 | 1,039 | 1,080 | 799.68 | 287.81 | |
Revenue Growth (YoY) | -14.64% | -3.79% | 35.06% | 177.85% | 12.91% |
Cost of Revenue | 281.43 | 288.5 | 386.79 | 341.62 | 195.48 |
Gross Profit | 605.52 | 750.57 | 693.26 | 458.06 | 92.33 |
Selling, General & Admin | 468.1 | 616.55 | 560.01 | 364.37 | 90.06 |
Research & Development | 27.15 | 24.07 | 30.17 | 27.12 | 6.7 |
Other Operating Expenses | 4.71 | 13.21 | 12.34 | 4.99 | 3.75 |
Operating Expenses | 499.96 | 652.47 | 611.43 | 401.75 | 101.65 |
Operating Income | 105.56 | 98.1 | 81.82 | 56.31 | -9.31 |
Interest Expense | - | -3.12 | -3.95 | -0.5 | -0.53 |
Interest & Investment Income | 0.8 | 7.25 | 7.17 | 4.3 | 2.32 |
Currency Exchange Gain (Loss) | - | -0 | 0.01 | 0.02 | -0.06 |
Other Non Operating Income (Expenses) | -23.44 | -0.56 | 0 | 2.1 | -0.11 |
EBT Excluding Unusual Items | 82.92 | 101.67 | 85.05 | 62.24 | -7.7 |
Impairment of Goodwill | - | - | - | - | -4.78 |
Gain (Loss) on Sale of Investments | -0 | -0.21 | - | - | - |
Gain (Loss) on Sale of Assets | -0.01 | -0.69 | -0.24 | - | 0.06 |
Asset Writedown | -1.77 | - | - | -0.1 | - |
Other Unusual Items | - | 2.82 | 12.2 | 4 | 7.67 |
Pretax Income | 81.15 | 103.59 | 97.02 | 66.14 | -4.75 |
Income Tax Expense | 15.78 | 51.68 | 13.17 | 17.49 | 1.55 |
Earnings From Continuing Operations | 65.36 | 51.91 | 83.85 | 48.65 | -6.3 |
Minority Interest in Earnings | -21.41 | -26.11 | -22.2 | -9.87 | -2.81 |
Net Income | 43.95 | 25.8 | 61.65 | 38.79 | -9.11 |
Net Income to Common | 43.95 | 25.8 | 61.65 | 38.79 | -9.11 |
Net Income Growth | 70.32% | -58.14% | 58.95% | - | - |
Shares Outstanding (Basic) | 303 | 303 | 303 | 303 | 304 |
Shares Outstanding (Diluted) | 303 | 303 | 303 | 303 | 304 |
Shares Change (YoY) | 0.03% | -0.05% | 0.05% | -0.10% | -0.54% |
EPS (Basic) | 0.14 | 0.09 | 0.20 | 0.13 | -0.03 |
EPS (Diluted) | 0.14 | 0.09 | 0.20 | 0.13 | -0.03 |
EPS Growth | 70.27% | -58.12% | 58.87% | - | - |
Free Cash Flow | -49.9 | 91.93 | -29.83 | 242.03 | 50.72 |
Free Cash Flow Per Share | -0.17 | 0.30 | -0.10 | 0.80 | 0.17 |
Dividend Per Share | - | 0.040 | 0.020 | - | - |
Dividend Growth | - | 100.00% | - | - | - |
Gross Margin | 68.27% | 72.23% | 64.19% | 57.28% | 32.08% |
Operating Margin | 11.90% | 9.44% | 7.58% | 7.04% | -3.24% |
Profit Margin | 4.96% | 2.48% | 5.71% | 4.85% | -3.16% |
Free Cash Flow Margin | -5.63% | 8.85% | -2.76% | 30.27% | 17.62% |
EBITDA | 149.27 | 135.57 | 111.73 | 83.3 | 13.25 |
EBITDA Margin | 16.83% | 13.05% | 10.34% | 10.42% | 4.60% |
D&A For EBITDA | 43.71 | 37.48 | 29.9 | 26.99 | 22.56 |
EBIT | 105.56 | 98.1 | 81.82 | 56.31 | -9.31 |
EBIT Margin | 11.90% | 9.44% | 7.58% | 7.04% | -3.24% |
Effective Tax Rate | 19.45% | 49.89% | 13.57% | 26.44% | - |
Revenue as Reported | - | 1,039 | 1,080 | 799.68 | 287.81 |
Advertising Expenses | - | 0.95 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.